Allecra Therapeutics is a company that provides Biopharmaceutical, Medicine, Gram-negative bacterial infections and more. Allecra Therapeutics is headquartered in Germany Baden-Wurttemberg. Allecra Therapeutics was founded in 2013. and was founded by Nicholas Benedict, Stuart Shapiro. Allecra Therapeutics has a total of 113 patents
Related Topics
BiopharmaceuticalMedicineGram-negative bacterial infectionsAntibiotic resistanceAntibioticsFidaxomicinCeftaroline fosamilCeftolozaneTelavancinRifampicinOritavancinAvibactamAntibacterial Drug ResistanceCeftazidime/avibactamDalbavancinImipenemCilastatinSolithromycinCeftobiproleAminoglycoside
visualizing technology portfolio of hot application areas and blank areas for Allecra Therapeutics
Time Range:
Overall
Overall
1 year
3 year
5 year
Application Domain L2
Application Domain L2
Application Domain L3
Application Domain L4
High-Tech Industry L1
High-Tech Industry L2
Tech Topic L2
Tech Topic L3
Timeline
Tech Topic L2
Tech Topic L2
Tech Topic L3
High-Tech Industry L1
High-Tech Industry L2
Application Domain L2
Application Domain L3
Application Domain L4
Download
Subsidiary Lists
Subsidiaries with patent applications for Allecra Therapeutics
Sign up to view the full data
Free Trial Now
Download
Top Related Companies
Sign up to view the full data
Free Trial Now
Allecra Therapeutics Frequently Asked Questions
What is Allecra Therapeutics's industry?
Allecra Therapeutics is in the industry of:Pharmaceutical and Medicine Manufacturing
What technical fields has Allecra Therapeutics researched?
Allecra Therapeutics has researched the technical fields related toBiopharmaceuticalMedicineGram-negative bacterial infectionsAntibiotic resistanceAntibioticsFidaxomicinCeftaroline fosamilCeftolozaneTelavancinRifampicinOritavancinAvibactamAntibacterial Drug ResistanceCeftazidime/avibactamDalbavancinImipenemCilastatinSolithromycinCeftobiproleAminoglycoside
What is Allecra Therapeutics's total number of patents?
Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat...